A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection

Valerio  Annese; Samadhan Bhaulal Patil; Chunxiao  Hu; Christos Giagkoulovits; Mohammed  Al-Rawhani,; James  Grant; Martin Macleod; David Clayton; Liam  Heaney; Ronan Daly; Claudio  Accarino; Yash Shah; Boon Cheah; James Beeley; Thomas   Jeffry Evans; Robert Jones; Michael   Barrett; David Cumming

doi:10.1038/s41378-021-00243-4

A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection

Valerio Annese, Samadhan Bhaulal Patil, Chunxiao Hu, Christos Giagkoulovits, Mohammed Al-Rawhani,, James Grant, Martin Macleod, David Clayton, Liam Heaney, Ronan Daly, Claudio Accarino, Yash Shah, Boon Cheah, James Beeley, Thomas Jeffry Evans, Robert Jones, Michael Barrett, David Cumming

Electronic Engineering

Research output: Contribution to journal › Article › peer-review

Abstract

There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor’s office to reduce the impact of serious disease. Many cancers are diagnosed late, leading to costly treatment and reduced life expectancy. With prostate cancer, the absence of a reliable test has inhibited the adoption of screening programs. We report a microelectronic point-of-care metabolite biomarker measurement platform and use it for prostate cancer detection. The platform, using an array of photodetectors configured to operate with targeted, multiplexed, colorimetric assays confined in monolithically integrated passive microfluidic channels, completes a combined assay of 4 metabolites in a drop of human plasma in under 2 min. A preliminary clinical study using L-amino acids, glutamate, choline, and sarcosine was used to train a cross-validated random forest algorithm. The system demonstrated sensitivity to prostate cancer of 94% with a specificity of 70% and an area under the curve of 0.78. The technology can implement many similar assay panels and hence has the potential to revolutionize low-cost, rapid, point-of-care testing.

Original language	English
Article number	21 (2021)
Number of pages	15
Journal	Microsystems and Nanoengineering
Volume	7
Early online date	15 Dec 2020
DOIs	https://doi.org/10.1038/s41378-021-00243-4
Publication status	Published - 5 Mar 2021

Bibliographical note

Keywords

Prostate cancer
CMOS
point of care
microfluidics
METABOLOMICS

Access to Document

10.1038/s41378-021-00243-4Licence: CC BY

s41378-021-00243-4
© The Author(s) 2021.
Final published version, 1.49 MBLicence: CC BY

Cite this

Annese, V., Patil, S. B., Hu, C., Giagkoulovits, C., Al-Rawhani, M., Grant, J., Macleod, M., Clayton, D., Heaney, L., Daly, R., Accarino, C., Shah, Y., Cheah, B., Beeley, J., Jeffry Evans, T., Jones, R., Barrett, M., & Cumming, D. (2021). A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, Article 21 (2021). https://doi.org/10.1038/s41378-021-00243-4

@article{2b942c96f4cd49dca1875385a958a125,

title = "A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection",

abstract = "There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor{\textquoteright}s office to reduce the impact of serious disease. Many cancers are diagnosed late, leading to costly treatment and reduced life expectancy. With prostate cancer, the absence of a reliable test has inhibited the adoption of screening programs. We report a microelectronic point-of-care metabolite biomarker measurement platform and use it for prostate cancer detection. The platform, using an array of photodetectors configured to operate with targeted, multiplexed, colorimetric assays confined in monolithically integrated passive microfluidic channels, completes a combined assay of 4 metabolites in a drop of human plasma in under 2 min. A preliminary clinical study using L-amino acids, glutamate, choline, and sarcosine was used to train a cross-validated random forest algorithm. The system demonstrated sensitivity to prostate cancer of 94% with a specificity of 70% and an area under the curve of 0.78. The technology can implement many similar assay panels and hence has the potential to revolutionize low-cost, rapid, point-of-care testing.",

keywords = "Prostate cancer, CMOS, point of care, microfluidics, METABOLOMICS",

author = "Valerio Annese and Patil, {Samadhan Bhaulal} and Chunxiao Hu and Christos Giagkoulovits and Mohammed Al-Rawhani, and James Grant and Martin Macleod and David Clayton and Liam Heaney and Ronan Daly and Claudio Accarino and Yash Shah and Boon Cheah and James Beeley and {Jeffry Evans}, Thomas and Robert Jones and Michael Barrett and David Cumming",

note = "{\textcopyright} The Author(s) 2021. ",

year = "2021",

month = mar,

day = "5",

doi = "10.1038/s41378-021-00243-4",

language = "English",

volume = "7",

journal = "Microsystems and Nanoengineering",

issn = "2096-1030",

publisher = "Nature Publishing Group",

}

Annese, V, Patil, SB, Hu, C, Giagkoulovits, C, Al-Rawhani, M, Grant, J, Macleod, M, Clayton, D, Heaney, L, Daly, R, Accarino, C, Shah, Y, Cheah, B, Beeley, J, Jeffry Evans, T, Jones, R, Barrett, M & Cumming, D 2021, 'A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection', Microsystems and Nanoengineering, vol. 7, 21 (2021). https://doi.org/10.1038/s41378-021-00243-4

TY - JOUR

T1 - A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection

AU - Annese, Valerio

AU - Patil, Samadhan Bhaulal

AU - Hu, Chunxiao

AU - Giagkoulovits, Christos

AU - Al-Rawhani,, Mohammed

AU - Grant, James

AU - Macleod, Martin

AU - Clayton, David

AU - Heaney, Liam

AU - Daly, Ronan

AU - Accarino, Claudio

AU - Shah, Yash

AU - Cheah, Boon

AU - Beeley, James

AU - Jeffry Evans, Thomas

AU - Jones, Robert

AU - Barrett, Michael

AU - Cumming, David

PY - 2021/3/5

Y1 - 2021/3/5

N2 - There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor’s office to reduce the impact of serious disease. Many cancers are diagnosed late, leading to costly treatment and reduced life expectancy. With prostate cancer, the absence of a reliable test has inhibited the adoption of screening programs. We report a microelectronic point-of-care metabolite biomarker measurement platform and use it for prostate cancer detection. The platform, using an array of photodetectors configured to operate with targeted, multiplexed, colorimetric assays confined in monolithically integrated passive microfluidic channels, completes a combined assay of 4 metabolites in a drop of human plasma in under 2 min. A preliminary clinical study using L-amino acids, glutamate, choline, and sarcosine was used to train a cross-validated random forest algorithm. The system demonstrated sensitivity to prostate cancer of 94% with a specificity of 70% and an area under the curve of 0.78. The technology can implement many similar assay panels and hence has the potential to revolutionize low-cost, rapid, point-of-care testing.

AB - There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor’s office to reduce the impact of serious disease. Many cancers are diagnosed late, leading to costly treatment and reduced life expectancy. With prostate cancer, the absence of a reliable test has inhibited the adoption of screening programs. We report a microelectronic point-of-care metabolite biomarker measurement platform and use it for prostate cancer detection. The platform, using an array of photodetectors configured to operate with targeted, multiplexed, colorimetric assays confined in monolithically integrated passive microfluidic channels, completes a combined assay of 4 metabolites in a drop of human plasma in under 2 min. A preliminary clinical study using L-amino acids, glutamate, choline, and sarcosine was used to train a cross-validated random forest algorithm. The system demonstrated sensitivity to prostate cancer of 94% with a specificity of 70% and an area under the curve of 0.78. The technology can implement many similar assay panels and hence has the potential to revolutionize low-cost, rapid, point-of-care testing.

KW - Prostate cancer

KW - CMOS

KW - point of care

KW - microfluidics

KW - METABOLOMICS

U2 - 10.1038/s41378-021-00243-4

DO - 10.1038/s41378-021-00243-4

M3 - Article

SN - 2096-1030

VL - 7

JO - Microsystems and Nanoengineering

JF - Microsystems and Nanoengineering

M1 - 21 (2021)

ER -